|
49 Companies |
|
64 Products |
|
64 Products |
|
51 Mechanisms of Action |
|
1 Trial |
|
275 News |
|
| 123456» |
- | oxaliplatin / Generic mfg., cisplatin / Generic mfg., gemcitabine / Generic mfg.
Trial completion, Enrollment change: Gemcitabine With Or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Bladder Cancer (clinicaltrials.gov) - Feb 18, 2025
P2, N=44, Completed, Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle
Suspended --> Completed | N=100 --> 44
- | Caprelsa (vandetanib) / Sanofi
Trial completion, Enrollment change, Metastases: CRUK-09/024: Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer (clinicaltrials.gov) - May 16, 2019
P2, N=82, Completed, Sponsor: Cardiff University
Suspended --> Completed | N=100 --> 44 Recruiting --> Completed | N=122 --> 82
- ||| sunitinib / Generic mfg.
Trial termination: Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer (clinicaltrials.gov) - May 1, 2019
P2, N=19, Terminated, Sponsor: Case Comprehensive Cancer Center
Recruiting --> Completed | N=122 --> 82 Completed --> Terminated
- | alisertib (MLN8237) / Puma
Trial completion, Enrollment change: Alisertib in Chemotherapy-pretreated Urothelial Cancer (clinicaltrials.gov) - Apr 19, 2019
P2, N=22, Completed, Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Completed --> Terminated Not yet recruiting --> Completed | N=130 --> 22
- || inodiftagene vixteplasmid (BC 819) / ChemomAb
Trial completion, Enrollment change, Trial completion date: Pilot Study of BC-819/PEI and BCG in Patients With Superficial Transitional Cell Bladder Carcinoma (clinicaltrials.gov) - Mar 11, 2019
P1, N=38, Completed, Sponsor: Anchiano Therapeutics Israel Ltd.
Not yet recruiting --> Completed | N=130 --> 22 Recruiting --> Completed | N=18 --> 38 | Trial completion date: Sep 2014 --> Oct 2017
- | Trial completion, Enrollment change: Microsatellite Analysis of Urinary Sediment in Detecting Bladder Cancer (clinicaltrials.gov) - Feb 8, 2019
P=N/A, N=125, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Recruiting --> Completed | N=18 --> 38 | Trial completion date: Sep 2014 --> Oct 2017 Active, not recruiting --> Completed | N=500 --> 125
- | Trial completion, Enrollment change, Surgery: Radiation Therapy or Surgery in Treating Patients Receiving Chemotherapy for Bladder Cancer (clinicaltrials.gov) - Jan 4, 2019
P3, N=45, Completed, Sponsor: Institute of Cancer Research, United Kingdom
Active, not recruiting --> Completed | N=500 --> 125 Active, not recruiting --> Completed | N=1015 --> 45
- veliparib (ABT-888) / AbbVie
Trial termination, Combination therapy, BRCA Biomarker, PARP Biomarker, Metastases: Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jan 3, 2019
P1, N=44, Terminated, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | N=1015 --> 45 Recruiting --> Terminated
- ||||| cabazitaxel / Generic mfg.
Enrollment change, Trial completion date, Trial primary completion date, Metastases: CabB1: Treatment of Locally Advanced or Metastatic Transitional Cell Carcinoma With Cabazitaxel (clinicaltrials.gov) - Dec 4, 2018
P2/3, N=20, Completed, Sponsor: Dr Anjali Zarkar
Recruiting --> Terminated N=96 --> 20 | Trial completion date: Dec 2015 --> Nov 2017 | Trial primary completion date: Dec 2014 --> Nov 2017
- | cisplatin / Generic mfg., sunitinib / Generic mfg., gemcitabine / Generic mfg.
Trial completion, Combination therapy, Metastases: Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT) (clinicaltrials.gov) - Oct 26, 2018
P2, N=63, Completed, Sponsor: Cardiff University
N=96 --> 20 | Trial completion date: Dec 2015 --> Nov 2017 | Trial primary completion date: Dec 2014 --> Nov 2017 Active, not recruiting --> Completed
- ||| cisplatin / Generic mfg., sunitinib / Generic mfg.
Trial completion, Metastases: SPRUCE: SU011248 for Platinum-Refractory Urothelial Cancer Evaluation Trial (clinicaltrials.gov) - Aug 22, 2018
P2, N=64, Completed, Sponsor: AHS Cancer Control Alberta
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || Javlor (vinflunine) / Pierre Fabre
Trial completion, Metastases: VINSOR: Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract (clinicaltrials.gov) - Aug 9, 2018
P1, N=22, Completed, Sponsor: Dr Anders Ull
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Avastin (bevacizumab) / Roche
Trial termination, Surgery, Metastases: Cisplatin, Bevacizumab, and Gemcitabine Followed by Surgery, Bevacizumab, and Paclitaxel in Treating Patients With Locally Advanced Nonmetastatic Bladder Cancer That Can Be Removed By Surgery (clinicaltrials.gov) - Jul 12, 2018
P2, N=21, Terminated, Sponsor: Medical University of South Carolina
Active, not recruiting --> Completed Completed --> Terminated
- | irinotecan / Generic mfg., gemcitabine / Generic mfg.
Enrollment change, Trial termination, Metastases: Gemcitabine and Irinotecan in Treating Patients With Locally Advanced or Metastatic Bladder Cancer (clinicaltrials.gov) - Jul 12, 2018
P2, N=16, Terminated, Sponsor: Medical University of South Carolina
Completed --> Terminated N=25 --> 16 | Completed --> Terminated; Low accrual
- Calsed (amrubicin) / BMS, Nippon Kayaku
Trial termination, Metastases: Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma (clinicaltrials.gov) - Jun 3, 2018
P2, N=22, Terminated, Sponsor: Matthew Galsky
N=25 --> 16 | Completed --> Terminated; Low accrual Active, not recruiting --> Terminated; due to a development decision by the funder
- ||| Ibrance (palbociclib) / Pfizer
Trial completion date, Trial termination, Metastases: Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line Chemotherapy (clinicaltrials.gov) - Jun 3, 2018
P2, N=12, Terminated, Sponsor: UNC Lineberger Comprehensive Cancer Center
Trial completion date: Jul 2018 --> Sep 2017 | Suspended --> Terminated; Data from first 12 subjects-primary endpoint not met. Data analysis underway.
- | Torisel (temsirolimus) / Pfizer
Enrollment change, Metastases: CRUK-08/015: Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium (clinicaltrials.gov) - Feb 6, 2018
P1/2, N=15, Completed, Sponsor: Cardiff University
Data analysis underway. N=99 --> 15
- | ganetespib (ADX-1612) / Aldeyra, Zaltrap (ziv-aflibercept IV) / Sanofi
Trial initiation date, Trial termination: Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas (clinicaltrials.gov) - Jan 30, 2018
P1, N=5, Terminated, Sponsor: National Cancer Institute (NCI)
N=99 --> 15 Initiation date: Jul 2014 --> Dec 2014 | Completed --> Terminated; Drug supplier suspended further clinical development of Ganetespib
- Javlor (vinflunine) / Pierre Fabre
Enrollment closed, Trial primary completion date, Metastases: VINSOR: Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract (clinicaltrials.gov) - Dec 29, 2017
P1, N=22, Active, not recruiting, Sponsor: Dr Anders Ull
Initiation date: Jul 2014 --> Dec 2014 | Completed --> Terminated; Drug supplier suspended further clinical development of Ganetespib Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2017 --> Oct 2017
- Ibrance (palbociclib) / Pfizer
Trial primary completion date, Metastases: Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line Chemotherapy (clinicaltrials.gov) - Dec 22, 2017
P2, N=12, Suspended, Sponsor: UNC Lineberger Comprehensive Cancer Center
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2017 --> Oct 2017 Trial primary completion date: Sep 2016 --> Jul 2018
- Ibrance (palbociclib) / Pfizer
Trial suspension, Trial primary completion date, Metastases: Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line Chemotherapy (clinicaltrials.gov) - Dec 14, 2017
P2, N=12, Suspended, Sponsor: UNC Lineberger Comprehensive Cancer Center
Trial primary completion date: Sep 2016 --> Jul 2018 Terminated --> Suspended | Trial primary completion date: Apr 2017 --> Sep 2016
- Ibrance (palbociclib) / Pfizer
Enrollment change, Trial termination, Metastases: Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line Chemotherapy (clinicaltrials.gov) - Oct 24, 2017
P2, N=12, Terminated, Sponsor: UNC Lineberger Comprehensive Cancer Center
N=40 --> 12 | Recruiting --> Terminated; Data from first 12 subjects-primary endpoint not met. Data analysis underway.
- | mocetinostat (MGCD0103) / Otsuka, BMS
Trial completion, Trial primary completion date, Metastases: Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes (clinicaltrials.gov) - Sep 1, 2017
P2, N=17, Completed, Sponsor: Mirati Therapeutics Inc.
Data analysis underway. Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Apr 2016
- | cisplatin / Generic mfg., doxorubicin hydrochloride / Generic mfg., vinblastine / Generic mfg.
Enrollment change, Trial initiation date, Trial termination: SWOG-4B951: 4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer (clinicaltrials.gov) - Jun 8, 2017
P3, N=521, Terminated, Sponsor: Southwest Oncology Group
Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Apr 2016 N=800 --> 521 | Initiation date: Sep 1998 --> Aug 1997 | Active, not recruiting --> Terminated; Accrual was halted on the basis of the Data and Safety Monitoring Board review of a futility analysis.
- | cabazitaxel / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy (clinicaltrials.gov) - May 11, 2017
P2, N=14, Completed, Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University
N=800 --> 521 | Initiation date: Sep 1998 --> Aug 1997 | Active, not recruiting --> Terminated; Accrual was halted on the basis of the Data and Safety Monitoring Board review of a futility analysis. Active, not recruiting --> Completed | N=33 --> 14 | Trial primary completion date: Aug 2017 --> Aug 2014
- | Trial primary completion date: Dual Energy CT vs Standard Triple Phase CT-A Randomised Control Trial (clinicaltrials.gov) - Apr 27, 2017
P=N/A, N=124, Completed, Sponsor: All India Institute of Medical Sciences, New Delhi
Active, not recruiting --> Completed | N=33 --> 14 | Trial primary completion date: Aug 2017 --> Aug 2014 Trial primary completion date: May 2016 --> Dec 2016
- lapatinib / Generic mfg., docetaxel / Generic mfg.
Trial primary completion date, Metastases: Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder (clinicaltrials.gov) - Apr 11, 2017
P2, N=15, Terminated, Sponsor: University of Southern California
Trial primary completion date: May 2016 --> Dec 2016 Trial primary completion date: Dec 2016 --> Jul 2013
- | Biomarker, Enrollment change, IO biomarker: Biomarkers in Patients With Kidney Cancer or Cancer of the Urothelium and in Healthy Participants (clinicaltrials.gov) - Apr 7, 2017
P=N/A, N=5, Completed, Sponsor: Wake Forest University Health Sciences
Trial primary completion date: Dec 2016 --> Jul 2013 N=40 --> 5
- | Phase classification: Merits of Performing a Modified Template Retroperitoneal Lymph Node Dissection (clinicaltrials.gov) - Mar 23, 2017
P=N/A, N=20, Completed, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
N=40 --> 5 Phase classification: P2 --> P=N/A
- Ibrance (palbociclib) / Pfizer
Trial primary completion date, Metastases: Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line Chemotherapy (clinicaltrials.gov) - Mar 14, 2017
P2, N=40, Recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Phase classification: P2 --> P=N/A Trial primary completion date: Jan 2020 --> Jul 2017
- | cisplatin / Generic mfg., sirolimus / Generic mfg., gemcitabine / Generic mfg.
Trial completion, Trial primary completion date: Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer (clinicaltrials.gov) - Mar 14, 2017
P1/2, N=21, Completed, Sponsor: University of Washington
Trial primary completion date: Jan 2020 --> Jul 2017 Active, not recruiting --> Completed | Trial primary completion date: Apr 2017 --> Aug 2016
- |||| Herceptin (trastuzumab) / Roche
Trial completion, Trial primary completion date: CVH-CT02: Efficacy of Combination of Trastuzumab to Gemcitabine - Platinum Advanced or Metastatic Urothelial Carcinoma (clinicaltrials.gov) - Feb 6, 2017
P2, N=61, Completed, Sponsor: Association Pour La Recherche des Th
Active, not recruiting --> Completed | Trial primary completion date: Apr 2017 --> Aug 2016 Active, not recruiting --> Completed | Trial primary completion date: May 2013 --> Feb 2010
- cisplatin / Generic mfg., sirolimus / Generic mfg., gemcitabine / Generic mfg.
Enrollment closed, Enrollment change: Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer (clinicaltrials.gov) - Jan 11, 2017
P1/2, N=21, Active, not recruiting, Sponsor: University of Washington
Active, not recruiting --> Completed | Trial primary completion date: May 2013 --> Feb 2010 Recruiting --> Active, not recruiting | N=45 --> 21
- Biomarker, Trial completion, Enrollment change, Trial initiation date, Trial primary completion date: Markers of Response to Intravesical Bladder Cancer Therapy (clinicaltrials.gov) - Dec 7, 2016
P=N/A, N=150, Completed, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting | N=45 --> 21 Active, not recruiting --> Completed | N=300 --> 150 | Initiation date: Aug 2009 --> Jun 2005 | Trial primary completion date: Aug 2017 --> Apr 2016
- Adstiladrin (nadofaragene firadenovec-vncg) / Ferring
Trial completion, Trial primary completion date: 1B Intravesical Administration of SCH 721015 (Ad-IFNa) in Admixture With SCH 209702 (Syn3) for The Treatment of BCG Refractory Superficial Bladder Cancer (clinicaltrials.gov) - Nov 28, 2016
P1b, N=7, Completed, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed | N=300 --> 150 | Initiation date: Aug 2009 --> Jun 2005 | Trial primary completion date: Aug 2017 --> Apr 2016 Active, not recruiting --> Completed | Trial primary completion date: Jan 2018 --> Nov 2016
- Adstiladrin (nadofaragene firadenovec-vncg) / Ferring
Trial primary completion date: 1B Intravesical Administration of SCH 721015 (Ad-IFNa) in Admixture With SCH 209702 (Syn3) for The Treatment of BCG Refractory Superficial Bladder Cancer (clinicaltrials.gov) - Oct 19, 2016
P1b, N=9, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed | Trial primary completion date: Jan 2018 --> Nov 2016 Trial primary completion date: Jan 2017 --> Jan 2018
- | albumin-bound paclitaxel / Generic mfg.
Trial completion, Trial primary completion date, Metastases: Single Agent Abraxane as Second Line Therapy in Bladder Cancer (clinicaltrials.gov) - Oct 17, 2016
P2, N=48, Completed, Sponsor: Sunnybrook Health Sciences Centre
Trial primary completion date: Jan 2017 --> Jan 2018 Recruiting --> Completed | Trial primary completion date: Jan 2011 --> Jun 2012
- Yervoy (ipilimumab) / BMS
Phase classification, Monotherapy: Study of Neoadjuvant Ipilimumab in Patients With Urothelial Carcinoma Undergoing Surgical Resection (clinicaltrials.gov) - Sep 30, 2016
P1b, N=12, Completed, Sponsor: Bristol-Myers Squibb
Recruiting --> Completed | Trial primary completion date: Jan 2011 --> Jun 2012 Phase classification: P1 --> P1b
- cabazitaxel / Generic mfg.
Trial primary completion date: Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy (clinicaltrials.gov) - Sep 9, 2016
P2, N=33, Active, not recruiting, Sponsor: Thomas Jefferson University
Phase classification: P1 --> P1b Trial primary completion date: Aug 2016 --> Aug 2017
- Javlor (vinflunine) / Pierre Fabre
Trial primary completion date, Metastases: VINSOR: Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract (clinicaltrials.gov) - Sep 1, 2016
P1, N=22, Recruiting, Sponsor: Dr Anders Ull
Trial primary completion date: Aug 2016 --> Aug 2017 Trial primary completion date: Dec 2015 --> Jan 2017
- cisplatin / Generic mfg., gemcitabine / Generic mfg.
Trial completion: Combination Chemotherapy in Treating Patients With Bladder Cancer (clinicaltrials.gov) - Jul 14, 2016
P3, N=42, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Trial primary completion date: Dec 2015 --> Jan 2017 Terminated --> Completed
- | NN1213 / Novo Nordisk
Trial completion, Surgery: Fenretinide in Treating Patients Who Have Undergone Surgery for Bladder Cancer (clinicaltrials.gov) - Jun 15, 2016
P3, N=111, Completed, Sponsor: M.D. Anderson Cancer Center
Terminated --> Completed No longer recruiting --> Completed
- Trial completion, Enrollment change, Trial primary completion date: Dual Energy CT vs Standard Triple Phase CT-A Randomised Control Trial (clinicaltrials.gov) - Jun 10, 2016
P=N/A, N=124, Completed, Sponsor: All India Institute of Medical Sciences, New Delhi
No longer recruiting --> Completed Recruiting --> Completed | N=100 --> 124 | Trial primary completion date: Nov 2015 --> May 2016
- | Trial completion, Enrollment change, Trial initiation date, Trial primary completion date: SELEBLAT: Selenium in Preventing Cancer Recurrence in Patients With Bladder Cancer (clinicaltrials.gov) - May 13, 2016
P3, N=276, Completed, Sponsor: Katholieke Universiteit Leuven
Recruiting --> Completed | N=100 --> 124 | Trial primary completion date: Nov 2015 --> May 2016 Recruiting --> Completed | N=900 --> 276 | Initiation date: Jun 2008 --> Sep 2009 | Trial primary completion date: Oct 2014 --> Dec 2015
- | everolimus / Generic mfg.
Trial completion, Trial primary completion date: AFINIVEST: The Efficacy of RAD 001 as Second Line Therapy in Patients With Transitional Cell Carcinoma TCC of the Urothelium (clinicaltrials.gov) - May 4, 2016
P3, N=53, Completed, Sponsor: Hopital Foch
Recruiting --> Completed | N=900 --> 276 | Initiation date: Jun 2008 --> Sep 2009 | Trial primary completion date: Oct 2014 --> Dec 2015 Recruiting --> Completed | Trial primary completion date: Jan 2014 --> Oct 2014
- cisplatin / Generic mfg., sirolimus / Generic mfg., gemcitabine / Generic mfg.
Trial primary completion date: Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer (clinicaltrials.gov) - Apr 28, 2016
P1/2, N=45, Recruiting, Sponsor: University of Washington
Recruiting --> Completed | Trial primary completion date: Jan 2014 --> Oct 2014 Trial primary completion date: Apr 2016 --> Apr 2017
- valrubicin / Generic mfg.
Trial completion: Phase I Study of Percutaneous Valrubicin for Upper Tract Urothelial Carcinoma (clinicaltrials.gov) - Apr 22, 2016
P1, N=4, Completed, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Trial primary completion date: Apr 2016 --> Apr 2017 Active, not recruiting --> Completed
- lapatinib / Generic mfg., docetaxel / Generic mfg.
Trial primary completion date, Metastases: Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder (clinicaltrials.gov) - Apr 9, 2016
P2, N=15, Terminated, Sponsor: University of Southern California
Active, not recruiting --> Completed Trial primary completion date: Dec 2015 --> Dec 2016
- | Trial completion: A Laser Detection for Bladder Cancer by (Photodynamic) Spectra of Urine (clinicaltrials.gov) - Mar 31, 2016
P3, N=100, Completed, Sponsor: Princess Al-Johara Al-Ibrahim Cancer Research Center
Trial primary completion date: Dec 2015 --> Dec 2016 Recruiting --> Completed
- ganetespib (ADX-1612) / Aldeyra, Zaltrap (ziv-aflibercept IV) / Sanofi
Trial completion, Enrollment change, Trial primary completion date: Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas (clinicaltrials.gov) - Feb 29, 2016
P1, N=2, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Recruiting --> Completed | N=26 --> 2 | Trial primary completion date: Mar 2017 --> Feb 2016